drugset / Trial / NCT07152223
Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
Withdrawn
Guangzhou Bio-gene Technology Co., Ltd
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, single-center Investigator-Initiated Trial (IIT) designed to evaluate the safety, pharmacokinetic profile, and preliminary efficacy of CD19-BCMA CAR-T cells in subjects diagnosed with connective tissue diseases.
Timeline
- Start
- 2025-08-07
- Primary completion
- 2026-03-02
- Completion
- 2026-03-02
Outcome
Outcome not reported
Stopped (Business): “Due to corporate strategic adjustment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T | Cell therapy | 1 cells/kg | Intravenous |
| Subject | CAR-T | Cell therapy | 3 cells/kg | Intravenous |